Researchers have developed a new antibody that can shut down the HIV virus for nearly a month with just a single dose.
According to Michel Nussenzweig at the Rockefeller University in New York, the agent, 3BNC3117, “is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV-1 prevention, therapy and cure.”
The goal, Nussenzweig says, is a once-a-year shot that would work as a preventative and, in combination with other treatments, an effective cure.
The 3BNC3117 antibody successfully suppressed 197 out of 237 strains of the virus and already proved successful in animal trials. In the Rockefeller University study, 17 HIV-positive subjects and 12 HIV-negative subjects were given a single dose and monitored for 56 days.
A statement explains more details:
At the highest dosage level tested in the study, 30 milligrams per kilogram of weight, all eight infected individuals treated showed up to 300-fold decreases in the amount of virus measured in their blood, with most reaching their lowest viral load one week after treatment.
The drop in viral load depended on the individual’s starting viral load and also the sensitivity of their particular strains of HIV to the antibody.
Previous attempts at HIV antibodies proved unsuccessful, but co-author Marina Caskey explains, “What’s special about these antibodies is that they have activity against over 80% of HIV strains and they are extremely potent.”
h/t: Gay Star News